UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl)
UvA-DARE (Digital Academic Repository)
Targeted therapies in rheumatoid arthritis
Boumans, M.J.H.
Publication date
2012
Link to publication
Citation for published version (APA):
Boumans, M. J. H. (2012). Targeted therapies in rheumatoid arthritis.
General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).
Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
TABLE OF CONTENTS
Chapter 1 General introduction 7
Section I The mechanism of action and clinical use of rituximab 17 Chapter 2 Rituximab treatment in rheumatoid arthritis: how does it work? 19 Chapter 3 Response to rituximab in patients with rheumatoid arthritis
in different compartments of the immune system 25 Chapter 4 Rituximab abrogates joint destruction in rheumatoid arthritis
by inhibiting osteoclastogenesis 39
Chapter 5 Progression of structural damage is not related to rituximab
serum levels in rheumatoid arthritis patients 53 Chapter 6 Biological treatment of rheumatoid arthritis: Towards a more
cost-effective retreatment regimen using rituximab? 63 Chapter 7 The relationship between the type I interferon signature
and the response to rituximab in rheumatoid arthritis 69 Section II Evaluation of potentially new treatments
for rheumatoid arthritis 81
Chapter 8 Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomized,
placebo-controlled, proof-of-concept study 83
Chapter 9 A Phase IIA, Randomized, Double-Blind, Placebo-Controlled Trial of Apilimod Mesylate, an IL-12/IL-23 Inhibitor, in Patients with
Rheumatoid Arthritis 99
Chapter 10 Summary and general discussion 113
Chapter 11 Nederlandse samenvatting 123
Dankwoord 127
Curriculum vitae 130